Molecular target structures in oncology;Molekulare zielstrukturen in der onkologie

Internist

Volumn 46, Issue 8, 2005, Pages 847-860

  Spiekermann, K ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Hematological neoplasias; Molecular target structures; Monoclonal antibodies; Oncological therapy; Protein tyrosine kinases

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EDRECOLOMAB; IBRITUMOMAB TIUXETAN; MYELOTARG; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; ENZYME ACTIVATION; EVALUATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; ONCOLOGY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; MOLECULAR BIOLOGY; NEOPLASMS;

EID: 23944444591     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1463-0     Document Type: Review

References (30)

1. Bagrintseva K, Schwab R, Kohl TM et al. (2004) Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acqui-red drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 103: 2266-2275
2. Baselga J, Albanell J (2002) Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 16: 1041-1063
3. Berger U, Engelich G, Reiter A, Hochhaus A, Hehlmann R (2004) Imatinib and beyond - the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Ann Hematol 83: 258-264
4. Bernstein ID (2002) CD33 as a target for selective ablation of acute myeloid leukemia. Clin Lymphoma 2: S9-11
5. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355-365
6. Branford S, Rudzki Z, Parkinson I et al. (2004) Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104: 2926-2932
7. Brass PF, Beitz J, Chen G et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7: 1490-1496
8. Buske C, Dreyling M, Unterhalt M, Hiddemann W (2004) [Monoclonal antibody treatment of malignant lymphoma]. Internist 45: 1370-1377
9. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648
10. Cools J, DeAngelo DJ, Gotlib J et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214
11. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825
12. Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345
13. Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480
14. Fenaux P, Chomienne C, Degos L (2001) All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 38: 13-25
15. Fukuoka M, Yano S, Giaccone G et al. (2003) Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246
16. Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8: 503-510
17. Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
18. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3: 655-664
19. Kobayashi S, Boggon TJ, Dayaram T et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792
20. Kris MG, Natale RB, Herbst RS et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158
21. Melnick A, Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215
22. O'Brien SG, Guilhot F, Larson RA et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004
23. Osborne CK, Zhao H, Fuqua SA (2000) Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18: 3172-3186
24. Paez JG, Janne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
25. Pao W, Wang TY, Riely GJ et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17. Epub 2005 Jan 25
26. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
27. Spiekermann K, Dirschinger RJ, Schwab R et al. (2003) The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 101: 1494-1504
28. Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54: 11-29
29. Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3: 650-665
30. Stone RM, DeAngelo DJ, Klimek V et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105: 54-60